Vivek Subbiah: A delight to host podcast on Neoadjuvant Exercise Therapy in Prostate Cancer

Vivek Subbiah shared a post on X by JAMA Oncology adding:

“Such a delight to host a JAMA Oncology podcast on a novel idea ‘Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial’ with the amazing Dr. Lee Jones.“

Quoting JAMA Oncology’s post below:

“Listen to an interview with Lee W. Jones author of ‘Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial’ with Vivek Subbiah. Hosted on AMA Ed Hub.”

View the podcast attached to the post.
Sources: Vivek Subbiah/X and JAMA Oncology/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.